Aortic stenosis classification: Difference between revisions
(70 intermediate revisions by 10 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | |||
{| class="infobox" style="float:right;" | |||
|- | |||
| [[File:Siren.gif|30px|link=Aortic stenosis resident survival guide]]|| <br> || <br> | |||
| [[Aortic stenosis resident survival guide|'''Resident'''<br>'''Survival'''<br>'''Guide''']] | |||
|} | |||
{{Aortic stenosis}} | {{Aortic stenosis}} | ||
{{CMG}}; | {{CMG}}; {{AE}}{{MC}} | ||
==Overview== | ==Overview== | ||
According to the 2020 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease, there are 4 stages of aortic stenosis based on the valve anatomy, valve hemodynamics, the left ventricular and vascular consequences of aortic obstruction, and the symptoms. The stages include at risk of AS, progressive hemodynamic obstruction, severe asymptomatic AS, and symptomatic AS. | |||
==Classification== | ==Classification== | ||
''' | According to the 2020 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease, there are 4 stages of aortic stenosis based on the valve anatomy, valve hemodynamics, the left ventricular and vascular consequences of aortic obstruction, and the symptoms of the patient: | ||
:* | * '''A''': Patient at risk of AS | ||
* '''B''': Progressive hemodynamic obstruction | |||
* '''C''': Severe asymptomatic AS | |||
* '''D''': Symptomatic AS | |||
Hemodynamic severity is assessed by transaortic maximum velocity or mean pressure gradient in the presence of a normal transaortic flow rate. However, some patients with AS have a low transaortic flow rate due to: | |||
: | * LV systolic dysfunction with a reduced LV ejection fraction (designated as D2) | ||
* Small hypertrophied LV with a low stroke volume (designated as D3) <ref name="pmid33332150">{{cite journal |vauthors=Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, O'Gara PT, Rigolin VH, Sundt TM, Thompson A, Toly C |title=2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines |journal=Circulation |volume=143 |issue=5 |pages=e72–e227 |date=February 2021 |pmid=33332150 |doi=10.1161/CIR.0000000000000923 |url=}}</ref> | |||
=== | {| style="border: 0px; font-size: 90%; margin: 3px;" align=center | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Stage | |||
# | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Definition | ||
# | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Valve Anatomy | ||
# | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Valve Hemodynamics | ||
# | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemodynamic Consequences | ||
# | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Symptoms | ||
|- | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | '''A''' | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | '''At risk of AS''' | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
* Bicuspid aortic valve (or other congenital valvular anomalies) | |||
* Aortic valve sclerosis | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
* Aortic Vmax <2 m/s | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
* None | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
* None | |||
|- | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | '''B''' | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | '''Progressive AS''' | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
* Mild to moderate leaflet calcification of a bicuspid or trileaflet valve with some reduction in systolic motion or | |||
* Rhematic valve changes with commissural fusion | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
* '''Mild AS''': Aortic Vmax 2.0-2.9 m/s or mean ΔP <20 mmHg | |||
* '''Moderate AS''': Aortic Vmax 3.0-3.9 m/s or mean ΔP 20-39 mmHg | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
* Early LV diastolic dysfunction may be present | |||
* Normal LVEF | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
* None | |||
|- | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | '''C:''' | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | '''Asymptomatic severe AS''' | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
|- | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | '''C1''' | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | '''Asymptomatic severe AS''' | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
* Severe leaflet calcification or congenital stenosis with severely reduced leaflet opening | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
* Aortic Vmax ≥ 4 m/s or mean ΔP ≥40 mmHg | |||
* AVA typically ≤ 1.0 cm<sup>2</sup> (or AVAi ≤ 0.6 cm<sup>2</sup>/m<sup>2) | |||
* Very severe AS: Aortic Vmax ≥ 5 m/s or mean ΔP ≥60 mmHg | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
* LV diastolic dysfunction | |||
* Mild LV hypertrophy | |||
* Normal LVEF | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
* None (Exercise testing is reasonable to confirm) | |||
|- | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | '''C2''' | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | '''Asymptomatic severe AS with LV dysfunction''' | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
* Severe leaflet calcification or congenital stenosis with severely reduced leaflet opening | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
* Aortic Vmax ≥ 4 m/s or mean ΔP ≥40 mmHg | |||
* AVA typically ≤ 1.0 cm<sup>2</sup> (or AVAi ≤ 0.6 cm<sup>2</sup>/m<sup>2) | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
* LVEF <50% | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
* None | |||
|- | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | '''D:''' | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | '''Symptomatic severe AS''' | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
|- | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | '''D1''' | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | '''Symptomatic severe high-grade AS''' | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
* Severe leaflet calcification or congenital stenosis with severely reduced leaflet opening | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
* Aortic Vmax ≥ 4 m/s or mean ΔP ≥40 mmHg | |||
* AVA typically ≤ 1.0 cm<sup>2</sup> (or AVAi ≤ 0.6 cm<sup>2</sup>/m<sup>2</sup>) but may be larger with mixed AS/AR | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
* LV diastolic dysfunction | |||
* LV hypertrophy | |||
* Pulmonary hypertension may be present | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
* Exertional dyspnea or decreased exercise tolerance | |||
* Exertional angina | |||
* Exertional syncope/presyncope | |||
|- | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | '''D2''' | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | '''Symptomatic severe low-flow/low-gradient AS with reduced LVEF''' | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
* Severe leaflet calcification with severely reduced leaflet motion | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
* AVA ≤1.0 cm<sup>2</sup> with resting aortic Vmax <4 m/s or mean ΔP <40 mmHg | |||
* Dobutamine stress echocardiography shows AVA ≤ 1.0 cm<sup>2</sup> with Vmax ≥4 m/s at any flow rate | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
* LV diastolic dysfunction | |||
* LV hypertrophy | |||
* LVEF <50% | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
* Heart failure | |||
* Angina | |||
* Syncope/presyncope | |||
|- | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | '''D3''' | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | '''Symptomatic severe low-gradient AS with normal LVEF or paradoxical low-flow severe AS''' | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
* Severe leaflet calcification with severely reduced leaftlet motion | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
* AVA ≤1.0 cm<sup>2</sup> with aortic Vmax <4 m/s or mean ΔP <40 mmHg | |||
* AVAi ≤0.6 cm<sup>2</sup>/m<sup>2</sup> and | |||
* Stroke volume index <35 ml/m<sup>2</sup> | |||
* Measured when patient is normotensive (systolic BP <140 mmHg) | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
* Increased LV relative wall thickness | |||
* Small LV chamber with low stroke volume | |||
* Restrictive diastolic filling | |||
* LVEF ≥50% | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | |||
* Heart failure | |||
* Angina | |||
* Syncope/presyncope | |||
|- | |||
|} | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[CME Category::Cardiology]] | |||
[[Category:Disease]] | |||
[[Category:Valvular heart disease]] | [[Category:Valvular heart disease]] | ||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
[[Category: | [[Category:Congenital heart disease]] | ||
[[Category:Cardiac surgery]] | [[Category:Cardiac surgery]] | ||
[[Category:Surgery]] | [[Category:Surgery]] | ||
Latest revision as of 02:52, 29 June 2022
Resident Survival Guide |
Aortic Stenosis Microchapters |
Diagnosis |
---|
Treatment |
Percutaneous Aortic Balloon Valvotomy (PABV) or Aortic Valvuloplasty |
Transcatheter Aortic Valve Replacement (TAVR) |
Case Studies |
Aortic stenosis classification On the Web |
American Roentgen Ray Society Images of Aortic stenosis classification |
Directions to Hospitals Treating Aortic stenosis classification |
Risk calculators and risk factors for Aortic stenosis classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mandana Chitsazan, M.D. [2]
Overview
According to the 2020 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease, there are 4 stages of aortic stenosis based on the valve anatomy, valve hemodynamics, the left ventricular and vascular consequences of aortic obstruction, and the symptoms. The stages include at risk of AS, progressive hemodynamic obstruction, severe asymptomatic AS, and symptomatic AS.
Classification
According to the 2020 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease, there are 4 stages of aortic stenosis based on the valve anatomy, valve hemodynamics, the left ventricular and vascular consequences of aortic obstruction, and the symptoms of the patient:
- A: Patient at risk of AS
- B: Progressive hemodynamic obstruction
- C: Severe asymptomatic AS
- D: Symptomatic AS
Hemodynamic severity is assessed by transaortic maximum velocity or mean pressure gradient in the presence of a normal transaortic flow rate. However, some patients with AS have a low transaortic flow rate due to:
- LV systolic dysfunction with a reduced LV ejection fraction (designated as D2)
- Small hypertrophied LV with a low stroke volume (designated as D3) [1]
Stage | Definition | Valve Anatomy | Valve Hemodynamics | Hemodynamic Consequences | Symptoms |
---|---|---|---|---|---|
A | At risk of AS |
|
|
|
|
B | Progressive AS |
|
|
|
|
C: | Asymptomatic severe AS | ||||
C1 | Asymptomatic severe AS |
|
|
|
|
C2 | Asymptomatic severe AS with LV dysfunction |
|
|
|
|
D: | Symptomatic severe AS | ||||
D1 | Symptomatic severe high-grade AS |
|
|
|
|
D2 | Symptomatic severe low-flow/low-gradient AS with reduced LVEF |
|
|
|
|
D3 | Symptomatic severe low-gradient AS with normal LVEF or paradoxical low-flow severe AS |
|
|
|
|
References
- ↑ Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, O'Gara PT, Rigolin VH, Sundt TM, Thompson A, Toly C (February 2021). "2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". Circulation. 143 (5): e72–e227. doi:10.1161/CIR.0000000000000923. PMID 33332150 Check
|pmid=
value (help).